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Chronic overnutrition drives complex adaptations within both professional metabolic and bystander tissues
that, despite intense investigation, are still poorly understood. Xu et al. (2013) now describe the unexpected
ability of adipose tissue macrophages to buffer lipids released from obese adipocytes in a manner indepen-
dent of inflammatory macrophage activation.In its simplest archetype, obesity’s funda-
mental characteristic is a surfeit of caloric
intake relative to energy expenditure. In
lean individuals, these excess calories
can be easily converted to lipid and stored
in white adipose tissue without significant
physiologic consequence. Chronic over-
nutrition, however, strains and eventually
exhausts this storage capacity, allowing
excess lipids to overflow into other phys-
iologic compartments less well suited to
nutrient handling, leading to significant
cellular stress responses and, eventually,
cellular dysfunction in both professional
metabolic and bystander tissues (Ode-
gaard and Chawla, 2013b). Despite its
salience in metabolic dysfunction, our
knowledge of the mechanisms underlying
adipose tissue’s lipid buffering capacity—
and, more importantly, how it fails in
obesity—is surprisingly incomplete. In
this issue of Cell Metabolism, Ferrante
and colleagues identify a previously un-
known mechanism by which triglycerides
and nonesterified fatty acids released by
overstretched adipocytes are buffered
by macrophages resident within the adi-
pose tissue, thereby partially shielding
other tissues from potentially toxic levels
of lipids (Xu et al., 2013) (Figure 1). Inter-
estingly, this macrophage phenotype
is enacted independently of traditional
markers of inflammatory activation.
The authors begin with tissue-wide
expression profiling of lean and obese
adipose tissues, which demonstrate sig-
natures for lipid uptake and lysosomal
oxidation. Together these signatures
describe a buffer into which adipocyte-
derived lipids are drawn and at least
partially catabolized (Xu et al., 2013).
Unexpectedly, this buffering mechanism
is located not within the adipocyte itselfbut within adipose tissue macrophages.
Moreover, this program was not present
in bone marrow-derived macrophages
but was induced specifically upon expo-
sure to adipose tissue-derived factors
in vitro, suggesting a tissue-specific func-
tional program similar to adipose tissue
regulatory T cells’ ability to regulate
adipocyte insulin signaling (Cipolletta
et al., 2012). Macrophage lipid uptake
itself, however, is not unique: macro-
phages have been widely implicated in
both functional and dysfunctional lipid
uptake in such varied contexts as athero-
sclerotic plaques, where lipid-engorged
macrophages termed ‘‘foam cells’’ form
the structural plurality of ‘‘fatty streak’’
lesions, and traumatic fat necrosis, where
macrophages clear fatty debris following
traumatic injury to adipose tissue such
as that which occurs postsurgically.
Indeed, lipid-laden macrophages have
also been previously described in non-
traumatized adipose tissue itself, where
they are found both as single cells and
asmultinucleated foreign-body giant cells
within the crown-like structures surround-
ing dead adipocytes (Cinti et al., 2005;
Prieur et al., 2011). Until now, functional
explanations for these lipid-laden popula-
tions have largely invoked debris clear-
ance and sequestration, often with little
empiric support, which stands in sharp
contrast to the active role in lipid buffering
described by Xu et al. in the current issue.
Interestingly, the ability of macrophages
to buffer adipocyte-derived lipids also ex-
plains the previously enigmatic observa-
tions that macrophages are recruited to
adipose tissue during weight loss (Mottillo
et al., 2007), a highly lipolytic context in
which the need for lipid buffering capacity
is high, and that their depletion by lipo-Cell Metabolism 18,somal clodronate results in increased
levels of nonesterified fatty acids being
released from the adipose tissue, a
finding compatible with the loss of buff-
ering capacity (Kosteli et al., 2010).
Although lipid levels and their dys-
regulation are unarguably critical in
obesity-related metabolic dysfunction,
inflammation of adipose and other tissue
beds has emerged as a central mecha-
nistic theme felt to be at least partially
independent of derangements in nutrient
concentrations (Odegaard and Chawla,
2013b). In the canonical model of obeso-
genesis, the expansion of adipose depots
is accompanied by a profound alteration
in composition and inflammatory timbre
of the tissue-associated leukocyte com-
partment. Numerically foremost among
these leukocytes, the macrophage popu-
lation expands from 10% of all cells in
lean adipose tissue to more than 50% in
advanced obesity and, based on bulk
tissue measurements, was thought to
swap an alternative (M2) activation
phenotype for a proinflammatory clas-
sical (M1) bias (Lumeng et al., 2007;
Weisberg et al., 2003). Indeed, assess-
ment of tissue levels of archetypal proin-
flammatory mediators such as TNF, IL1b,
and iNOS appears to support this
hypothesis; however, a growing body of
recent reports focusing on per-cell mea-
surements has begun to question the
accuracy of this dogma. Indeed, Ferrante
and colleagues also observe that
the macrophage phenotype during obe-
sogenesis fails to conform to the
accepted M2-M1 shift paradigm, instead
eschewing TNF and many other canon-
ical markers of M1 activation during
obesity for a more complex immunophe-
notype that does not conform to eitherDecember 3, 2013 ª2013 Elsevier Inc. 767
Figure 1. Adipose Tissue Macrophages Buffer Local Lipid Levels through a Program of
Lysosomal Lipid Metabolism
Chronic overnutrition dramatically remodels adipose tissue architecture, driving adipocyte expansion and
the infiltration of numerous immune cells, including macrophages. Triglycerides released from overbur-
dened adipocytes are taken up by tissue-resident macrophages that function to buffer fatty acid release
into circulation through a lysosome-dependent mechanism of lipid catabolism. ATM, adipose tissue mac-
rophages.
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Previewstraditional macrophage activation arche-
type (Xu et al., 2013).
It is important to note, however, that
these findings do not conflict with the liter-
ature regarding the importance or contri-
butions of classical (M1) and alternative
(M2)macrophage activation; the evidence
still strongly supports that relative loss of
M2 activation potential (i.e., through
genetic intervention) or gain of M1 ex-
acerbates metabolic dysfunction in diet-
induced obesity (Odegaard and Chawla,
2013b). Rather, it now appears that while
macrophage activation programs do
exert diametrically opposed influences
on energy metabolism, their relative
balance either changes less or, perhaps,
shifts in a more complex way than previ-
ously thought. Indeed, with the more
recent surveys ascribing significantly
more diversity to the adipose tissue-asso-
ciated leukocyte pool than initially appre-
ciated (Odegaard and Chawla, 2013a), it
is possible that the inflammatory evolution768 Cell Metabolism 18, December 3, 2013 ªpostulated from bulk tissue measure-
ments reflects more the numeric and
qualitative inflammatory shifts in nonma-
crophage lineages than those in the
macrophage compartment itself.
Collectively, the authors demonstrate
that adipose tissue macrophages buffer
lipids released from over-engorged adi-
pocytes in a manner independent from
canonical macrophage activation arche-
types. These important findings challenge
prevailing dogma regarding macrophage
function in adipose tissue and raise
many important questions. First and fore-
most, can this buffering mechanism be
exploited for therapeutic effect? Current
and previous studies suggest that
augmentation of this pathway might
ameliorate the lipotoxicity often seen in
obesity-related metabolic dysfunction;
however, how this might be accom-
plished or what the aggregate effects of
such augmentation might be are entirely
unclear. Furthermore, the increasingly2013 Elsevier Inc.complex picture of the adipose tissue
macrophage in obesity has implications
for the burgeoning efforts to therapeuti-
cally target this cell; given seemingly dual-
istic contributions, what might the effects
of macrophage-targeted therapy be?
Might inhibition of macrophage inflamma-
tion similarly squelch an important lipid
buffer, leaving other tissues increasingly
susceptible to lipotoxic sequelae? Or
might augmentation of this lipid buffer un-
wittingly also augment inflammation in the
macrophage or elsewhere, mitigating
short-term consequences of the problem
but perpetuating and exacerbating root
causes? Clearly, the observations pre-
sented in this study represent an impor-
tant advance and raise many interesting
questions that bear heavily on the
future of many antiobesity therapeutic ap-
proaches currently under development.REFERENCES
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